ALKS or CSLLY: Which Is the Better Value Stock Right Now?

Zacks Investment Research has identified Alkermes (ALKS) as the superior value stock compared to CSL Limited Sponsored ADR (CSLLY) within the Medical - Biomedical and Genetics sector. ALKS holds a Zacks Rank of #1 (Strong Buy) due to improving earnings outlook, contrasting with CSLLY's #4 (Sell). Valuation metrics further support this, with ALKS exhibiting a lower forward P/E of 16.00 (vs. CSLLY's 24.13), a lower PEG ratio of 1.30 (vs. 1.93), and a lower P/B ratio of 3.12 (vs. 3.73), resulting in a Value grade of B for ALKS against CSLLY's C.

Analysis

A comparative analysis within the Medical - Biomedical and Genetics sector identifies Alkermes (ALKS) as a more compelling value investment than CSL Limited Sponsored ADR (CSLLY). This assessment is primarily driven by analyst sentiment and fundamental valuation metrics. ALKS holds a Zacks Rank of #1 (Strong Buy), reflecting a positive trend in earnings estimate revisions and an improving analyst outlook. In contrast, CSLLY is rated #4 (Sell), indicating negative revision activity. On a valuation basis, ALKS trades at a significant discount to its peer, with a forward P/E ratio of 16.00 versus CSLLY's 24.13. This valuation gap is further supported by the PEG ratio, where ALKS's 1.30 suggests a more reasonable price relative to its expected earnings growth compared to CSLLY's 1.93. Additionally, Alkermes exhibits a lower Price-to-Book (P/B) ratio of 3.12 against CSL's 3.73. The combination of a superior earnings outlook and more attractive multiples across P/E, PEG, and P/B metrics results in ALKS receiving a 'B' grade for Value, while CSLLY receives a 'C'.

Key Decisions for Investors

• Value-oriented investors should consider Alkermes (ALKS) as a potential long position, given its strong buy rating, positive earnings estimate momentum, and more attractive valuation multiples compared to its peer.
• Investors currently holding CSL Limited (CSLLY) should re-evaluate their position due to its 'Sell' rating, which signals a negative earnings outlook and a relatively expensive valuation that could lead to underperformance.
• The primary driver in this comparison is the divergence in earnings estimate revisions, so monitoring future analyst estimate trends for both ALKS and CSLLY will be critical for validating or challenging this investment thesis.